2022年6月1日 · Men with unfavorable intermediate-risk (UIR-PCa) or high-risk prostate cancer (HR-PCa) are often treated with definitive external beam radiotherapy (EBRT) plus androgen deprivation therapy. Treatment is frequently intensified by electively treating the pelvic lymph nodes (LNs) with whole pelvis radiotherapy (WPRT), but practice patterns and the ...

2025年2月18日 · Background: Major clinical guidelines including the American Urology Association (AUA) defines unfavorable intermediate-risk prostate cancer (UIR-PCa) according to diagnostic PSA, clinical stage, biopsy positive cores, and Gleason grade group (GG). The current AUA guidelines separate patients into 3 primary groups: 1) GG1 with PSA 10-20 and ...

Men with unfavorable intermediate-risk (UIR-PCa) or high-risk prostate cancer (HR-PCa) are often treated with definitive external beam radiotherapy (EBRT) plus androgen deprivation therapy (ADT). Treatment is frequently intensified by electively treating the pelvic lymph nodes (LN) with whole pelvis radiotherapy (WPRT), but practice patterns ...

2016年6月8日 · Patients in the UIR PCa group with a PSA value <0.7 ng/mL at first follow-up had significant better bRFS, LF and MFS. Risk factors currently not included in the guidelines are useful to stratify patients with intermediate-risk PCa in two groups of different prognosis even when HyRT is delivered.

2022年2月16日 · Background: Men with unfavorable intermediate-risk (UIR-PCa) or high-risk prostate cancer (HR-PCa) are often treated with definitive external beam radiotherapy (EBRT) plus androgen deprivation therapy (ADT). Treatment is frequently intensified by electively treating the pelvic lymph nodes with whole pelvis radiotherapy (WPRT), but practice ...

2022年2月25日 · 患有预后不良的中危（UIR-PCa）或高危前列腺癌（HR-PCa）的男性通常采用确定的体外放射治疗（EBRT）加雄性激素剥夺治疗（ADT）。 可通过选择用全盆腔放疗 (WPRT)治疗盆腔淋巴结 (LN)来加强治疗，但实践模式和WPRT的好处并没有得到很好阐释。 近期，来自美国的研究人员在《J Urol》上发表文章， 研究人员假设，相对于仅接受前列腺放疗的男性，接受WPRT治疗的男性的总生存率（OS）会有所提高。 研究人员回顾了2008-2015年期间 …

Purpose: Men with unfavorable intermediate-risk (UIR-PCa) or high-risk prostate cancer (HR-PCa) are often treated with definitive external beam radiotherapy (EBRT) plus androgen deprivation therapy. Treatment is frequently intensified by electively treating the pelvic lymph nodes (LNs) with whole pelvis radiotherapy (WPRT), but practice ...

2016年6月8日 · Patients in the UIR PCa group with a PSA value <0.7 ng/mL at first follow-up had significant better bRFS, LF and MFS. Conclusions: Risk factors currently not included in the guidelines are useful to stratify patients with intermediate-risk PCa in two groups of different prognosis even when HyRT is delivered.

Background: Current recommendations regarding radiotherapy treatment for unfavorable intermediate-risk prostate cancer (UIR-PCa) include external beam radiotherapy (EBRT) ± brachytherapy boost (BT) ± androgen deprivation therapy (ADT). The ideal radiotherapy treatment approach for UIR-PCa has not been well-defined.

2021年5月10日 · The study involved 5693 patients diagnosed between 1994 and 2019 with low-risk, FIR, and unfavorable intermediate-risk (UIR) PCa (stratification according to the AUA guidelines) who underwent RP.